About Us
The American Society for Experimental Neurotherapeutics (ASENT) is an independent non-profit organization established in 1997 by leaders in academia, government, advocacy and industry to facilitate the process by which new therapies are made available to patients with neurological disorders. Its primary goal is to encourage and advance the development of improved therapies for diseases and disorders of the nervous system.
ASENT engages in scientific exchanges to encourage contacts between those involved in the discovery and development of neurotherapeutics and to provide opportunities for dialogue between the interested groups. The society organizes education and training and publishes a journal for healthcare practitioners, scientists and officials participating in the neurotherapeutics field, which serves as a forum for its members and interested groups addressing diverse issues.
Vision, Mission, Goals and Team
To advance the science of neurotherapeutics and to improve and accelerate the development of new treatments
ASENT combines academia, government, clinical community, industry and advocacy to enable and advance the discovery, translation and development of neurotherapeutics.
Drive the development of next generation therapeutics through world-class dialogue. Promote the highest scientific and ethical principles in therapeutic discovery and clinical investigation. Create a strong organization scaffold to support ASENT.
Executive Director
Director of Operations
Thank You to Our Sponsors
“The ASENT Annual Meeting features great topics and interactions. It is unlike any other meeting.”
~ Member, Chair of Neurology
ASENT Career Center
Recent Publications on COVID-19
Pneumonia and respiratory infections in Down syndrome: A scoping review of the literature
Santoro SL, Chicoine B, Jasien JM, Kim JL, Stephens M, Bulova P and Capone G
Pneumonia and respiratory infections in Down syndrome: A scoping review of the literature
Santoro SL, Chicoine B, Jasien JM, Kim JL, Stephens M, Bulova P and Capone G
Pneumonia and respiratory infections impact infants and children with Down syndrome; pneumonia is a leading cause of mortality in adults with Down syndrome. We aimed to review the literature to evaluate gaps and address key questions. A series of key questions were formulated a priori to inform the search strategy and review process; addressed prevalence, severity, etiology, risk factors, preventive methods, screening, and financial costs, potential benefits or harms of screening. Using the National Library of Medicine database, PubMed, detailed literature searches on pneumonia and respiratory infections in Down syndrome were performed. Previously identified review articles were also assessed. The quality of available evidence was then evaluated and knowledge gaps were identified. Forty-two relevant original articles were identified which addressed at least one key question. Study details including research design, internal validity, external validity, and relevant results are presented. Pneumonia and respiratory infections are more prevalent and more severe in individuals with Down syndrome compared to healthy controls through literature review, yet there are gaps in the literature regarding the etiology of pneumonia, the infectious organism, risk factors for infection, and to guide options for prevention and screening. There is urgent need for additional research studies in Down syndrome, especially in the time of the current COVID-19 pandemic.
B cell targeting therapies in MS patients during the SARS-CoV-2 pandemic – when immunosuppression meets infection?
Mycko MP
B cell targeting therapies in MS patients during the SARS-CoV-2 pandemic – when immunosuppression meets infection?
Mycko MP
Research into the mechanisms of autoimmune demyelination have highlighted B cells in this process. Therapies targeting this population were a recent addition to the multiple sclerosis (MS) drugs portfolio. The SARS-CoV-2 pandemic and the risk of severe COVID-19 have challenged the safety of B cell depletion in MS patients.
Biobanking for COVID-19 research
Rovere-Querini P, Tresoldi C, Conte C, Ruggeri A, Ghezzi S, De Lorenzo R, Di Filippo L, Farina N, Ramirez GA, Ripa M, Mancini N, Cantarelli E, Galli L, Poli A, De Cobelli F, Bonini C, Manfredi AA, Franchini S, Spessot M, Carlucci M, Dagna L, Scarpellini P, Ambrosio A, Di Napoli D, Bosi E, Tresoldi M, Lazzarin A, Landoni G, Martino G, Zangrillo A, Poli G, Castagna A, Vicenzi E, Clementi M, Ciceri F and
Biobanking for COVID-19 research
Rovere-Querini P, Tresoldi C, Conte C, Ruggeri A, Ghezzi S, De Lorenzo R, Di Filippo L, Farina N, Ramirez GA, Ripa M, Mancini N, Cantarelli E, Galli L, Poli A, De Cobelli F, Bonini C, Manfredi AA, Franchini S, Spessot M, Carlucci M, Dagna L, Scarpellini P, Ambrosio A, Di Napoli D, Bosi E, Tresoldi M, Lazzarin A, Landoni G, Martino G, Zangrillo A, Poli G, Castagna A, Vicenzi E, Clementi M, Ciceri F and
Biobanks are imperative infrastructures, particularly during outbreaks, when there is an obligation to acquire and share knowledge as quick as possible to allow for implementation of science-based preventive, diagnostic, prognostic and therapeutic strategies.
Stroke care in Italy: An overview of strategies to manage acute stroke in COVID-19 time
Zedde M, Pezzella FR, Paciaroni M, Corea F, Reale N, Toni D and Caso V
Stroke care in Italy: An overview of strategies to manage acute stroke in COVID-19 time
Zedde M, Pezzella FR, Paciaroni M, Corea F, Reale N, Toni D and Caso V
To analyse structural and non-structural modifications of acute stroke care pathways undertaken at healthcare institutions across the regions of Italy due to the coronavirus disease 2019 (COVID-19) pandemic.
Maintaining stroke care in Europe during the COVID-19 pandemic: Results from an international survey of stroke professionals and practice recommendations from the European Stroke Organisation
Aguiar de Sousa D, van der Worp HB, Caso V, Cordonnier C, Strbian D, Ntaios G, Schellinger PD, Sandset EC and
Maintaining stroke care in Europe during the COVID-19 pandemic: Results from an international survey of stroke professionals and practice recommendations from the European Stroke Organisation
Aguiar de Sousa D, van der Worp HB, Caso V, Cordonnier C, Strbian D, Ntaios G, Schellinger PD, Sandset EC and
The coronavirus disease 2019 (COVID-19) pandemic has been placing an overwhelming burden on health systems, thus threatening their ability to operate effectively for acute conditions in which treatments are highly time sensitive, such as cerebrovascular disorders and myocardial infarction. As part of an effort to reduce the consequences of this outbreak on health service delivery to stroke patients, the European Stroke Organisation has undertaken a survey aimed at collecting information on the provision of stroke care during the pandemic.
